The Office of the United States Trade Representative (USTR) has launched a Section 301 investigation into China's acts, policies, and practices concerning illicit fentanyl, following a petition. This investigation will assess China's contribution to the global fentanyl crisis and its impact on the United States. The USTR will examine the nature and extent of China's alleged involvement in the fentanyl supply chain.

This action signifies a potential for future trade actions or sanctions against China if the investigation uncovers trade-distorting practices or other violations of trade agreements. While this is an investigative stage, regulated entities involved in trade with China, particularly those in the pharmaceutical and chemical sectors, should monitor developments. The USTR has not yet specified a comment deadline or compliance actions, but such investigations can lead to significant trade policy changes.